Literature DB >> 21176983

Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison.

Marco Schwarz1, Alessio Pierelli, Claudio Fiorino, Francesco Fellin, Giovanni Mauro Cattaneo, Cesare Cozzarini, Nadia Di Muzio, Riccardo Calandrino, Lamberto Widesott.   

Abstract

PURPOSE: To compare helical tomotherapy (HT) and intensity modulated proton therapy (IMPT) on early stage prostate cancer treatments delivered with simultaneous integrated boost (SIB) in moderate hypofractionation. MATERIAL/
METHODS: Eight patients treated with HT were replanned with two-field IMPT (2fIMPT) and five-field IMPT (5fIMPT), using a small pencil beam size (3 mm sigma). The prescribed dose was 74.3 Gy in 28 fractions on PTV1 (prostate) and PTV2 (proximal seminal vesicles), 65.5 Gy on PTV3 (distal seminal vesicles) and on the overlap between rectum and PTVs.
RESULTS: IMPT and HT achieved similar target coverage and dose homogeneity, with 5fIMPT providing the best results. The conformity indexes of IMPT were significantly lower for PTV1+2 and PTV3. Above 65 Gy, HT and IMPT were equivalent in the rectum, while IMPT spared the bladder and the penile bulb from 0 to 70 Gy. From 0 up to 60 Gy, IMPT dosimetric values were (much) lower for all OARs except the femur heads, where HT was better than 2fIMPT in the 25-35 Gy dose range. OARs mean doses were typically reduced by 30-50% by IMPT. NTCPs for the rectum were within 1% between the two techniques, except when the endpoint was stool frequency, where IMPT showed a small (though statistically significant) benefit.
CONCLUSIONS: HT and IMPT produce similar dose distributions in the target volume. The current knowledge on dose-effect relations does not allow to quantify the clinical impact of the large sparing of IMPT at medium-to-low doses. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21176983     DOI: 10.1016/j.radonc.2010.10.027

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

2.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

3.  Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer.

Authors:  Charles B Simone; David Ly; Tu D Dan; John Ondos; Holly Ning; Arnaud Belard; John O'Connell; Robert W Miller; Nicole L Simone
Journal:  Radiother Oncol       Date:  2011-06-12       Impact factor: 6.280

4.  Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors.

Authors:  Thomas J Pugh; Richard A Amos; Sandra John Baptiste; Seungtaek Choi; Quyhn Nhu Nguyen; X Ronald Zhu; Matthew B Palmer; Andrew K Lee
Journal:  Med Dosim       Date:  2013-06-06       Impact factor: 1.482

Review 5.  Proton therapy for prostate cancer: current state and future perspectives.

Authors:  Yao-Yu Wu; Kang-Hsing Fan
Journal:  Br J Radiol       Date:  2021-09-24       Impact factor: 3.039

6.  Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.

Authors:  Thomas J Pugh; Mark F Munsell; Seungtaek Choi; Quyhn Nhu Nguyen; Benson Mathai; X Ron Zhu; Narayan Sahoo; Michael Gillin; Jennifer L Johnson; Richard A Amos; Lei Dong; Usama Mahmood; Deborah A Kuban; Steven J Frank; Karen E Hoffman; Sean E McGuire; Andrew K Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-15       Impact factor: 7.038

7.  Pediatric Craniospinal Irradiation - The implementation and Use of Normal Tissue Complication Probability in Comparing Photon versus Proton Planning.

Authors:  S Balasubramanian; M K Shobana
Journal:  J Med Phys       Date:  2021-11-20

8.  Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy.

Authors:  Yihang Xu; Nellie Brovold; Jonathan Cyriac; Elizabeth Bossart; Kyle Padgett; Michael Butkus; Tejan Diwanj; Adam King; Alan Dal Pra; Matt Abramowitz; Alan Pollack; Nesrin Dogan
Journal:  Int J Part Ther       Date:  2021-06-15

9.  A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma.

Authors:  Sergiu Scobioala; Christopher Kittel; Nicolas Wissmann; Uwe Haverkamp; Mohammed Channaoui; Omar Habibeh; Khaled Elsayad; Hans Theodor Eich
Journal:  Radiat Oncol       Date:  2016-09-27       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.